Pharmaron profit drops 37% despite revenue growth

Pharmaron Beijing reported revenue of RMB6.44 billion for the first half of 2025, up 14.9% year-on-year, with gross profit rising 17.5% to RMB2.17 billion.

However, profit attributable to owners fell 37.0% to RMB701.4 million, mainly due to the absence of investment income from disposing equity interests in PROTEOLOGIX seen in the prior year.

Net cash flows from operating activities jumped 28.1% to RMB1.41 billion. The board declared no interim dividend.